Skyrizi (risankizumab-rzaa) is a prescription injection that’s used to treat certain autoimmune disorders, such as plaque psoriasis and Crohn’s disease. Skyrizi comes in a few different forms ...

Patients may self-inject Skyrizi after training in subcutaneous injection technique. In April 2021, the Food and Drug Administration (FDA) approved the supplemental Biologics License Application ...

Previously two 75 mg injections per dose, SKYRIZI 150 mg is now administered with one injection per dose – via either a prefilled pen or syringe – every 12 weeks following two starter doses.

Back to Healio Skyrizi is now available as a single-dose 150 mg injection for the treatment of adults with moderate to severe plaque psoriasis in the United States, AbbVie announced in a press ...

(RTTNews) - AbbVie (ABBV) announced that SKYRIZI, an interleukin-23 inhibitor, is now available in the U.S. as a single-dose 150 mg injection for the treatment of adults with moderate to severe ...

"That's why we're proud to provide an updated SKYRIZI treatment experience that allows for fewer injections of the same SKYRIZI that patients and providers have come to know and trust." ...